| ln Vitro |
MART-1 (27-35) (human) (TFA) (10⁻⁷-10⁻⁵ M; incubated at room temperature for 2 hours, then at 4 °C for 24 hours) can bind to purified HLA-A2 molecules and be detected by fluorescence signal [1]. MART-1 (27-35) (human) (TFA) (10⁻⁵ M; incubated overnight at 4 °C to form an initial complex) can form an HLA-A2 complex, which is almost completely dissociated within 24 hours at 37 °C [1]. MART-1 (27-35) (human) (TFA) (1 μg/mL; incubated with T2 cells for 1 hour, cell lysis assay after 4 hours) can be recognized by human MART-1 (27-35) specific, HLA-A2 restricted TIL clones LT8, LT11 and LT12, inducing T2 target cells to release high levels of 51Cr, and the half maximum lysis concentration of clone LT12 on T2 cells is 1.1 × 10-9 M[1]. MART-1 (27-35) (human) (TFA) (10-10-10-5 g/mL; 1 hour) in a dose-dependent manner sensitized HLA-A*0201+ T2 cells to cleavage of CLW anti-MART-1(27-35) CD8+ CTLs, with significant cleavage at 10-8 g/mL and 100% maximum specific 51Cr release at 10-5 g/mL [2].
|
|---|---|
| Cell Assay |
Cytotoxicity assay [2]
Cell Types: HLA-A*0201+ T2 target cells, anti-MART-1 (27-35) CD8+ CTL cell line (CLW) Tested Concentrations: 10⁻¹⁰⁰⁰⁵ g/mL Incubation Duration: 1 hour (incubation with target cells) Experimental Results: Induced dose-dependent specific release of 51Cr from T2 cells. Significant cell lysis was achieved at concentrations of 10⁻⁸ g/mL and above. 100% maximum specific 51Cr release was achieved at the highest test concentration (10⁻⁵ g/mL). |
| References |
|
| Molecular Formula |
C37H67N9O11.XC2HF3O2
|
|---|---|
| Molecular Weight |
813.98 (free base)
|
| Related CAS # |
MART-1 (27-35) (human)
|
| Sequence |
Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-ValAAGIGILTV
|
| SequenceShortening |
AAGIGILTV
|
| Appearance |
White to off-white solid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.14 mg/mL (ultrasonic and warming and heat to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
